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Many forms of long-lasting behavioral and synaptic plasticity
require the synthesis of new proteins. For example, long-term
potentiation (LTP) that endures for more than an hour requires
both transcription and translation. The signal-transduction mech-
anisms that couple synaptic events to protein translational ma-
chinery during long-lasting synaptic plasticity, however, are not
well understood. One signaling pathway that is stimulated by
growth factors and results in the translation of specific mRNAs
includes the rapamycin-sensitive kinase mammalian target of rapa-
mycin (mTOR, also known as FRAP and RAFT-1). Several compo-
nents of this translational signaling pathway, including mTOR,
eukaryotic initiation factor-4E-binding proteins 1 and 2, and eu-
karyotic initiation factor-4E, are present in the rat hippocampus as
shown by Western blot analysis, and these proteins are detected
in the cell bodies and dendrites in the hippocampal slices by
immunostaining studies. In cultured hippocampal neurons, these
proteins are present in dendrites and are often found near the
presynaptic protein, synapsin I. At synaptic sites, their distribution
completely overlaps with a postsynaptic protein, PSD-95. These
observations suggest the postsynaptic localization of these pro-
teins. Disruption of mTOR signaling by rapamycin results in a
reduction of late-phase LTP expression induced by high-frequency
stimulation; the early phase of LTP is unaffected. Rapamycin also
blocks the synaptic potentiation induced by brain-derived neuro-
trophic factor in hippocampal slices. These results demonstrate an
essential role for rapamycin-sensitive signaling in the expression of
two forms of synaptic plasticity that require new protein synthesis.
The localization of this translational signaling pathway at postsyn-
aptic sites may provide a mechanism that controls local protein
synthesis at potentiated synapses.
Enduring changes in synaptic strength, such as long-termpotentiation (LTP) in the mammalian brain or long-term
facilitation (LTF) in Aplysia neurons, are one mechanism by
which nervous systems can store information for long periods.
Changes that underlie short-term plasticity can be accomplished
by covalent modifications of preexisting proteins. New protein
synthesis, however, is required for long-lasting LTP (L-LTP) (1,
2), neurotrophin-induced synaptic potentiation (3), and LTF in
Aplysia (4), and for long-term behavioral memory in intact
animals (5). Newly synthesized proteins are thought to deposit in
activated synapses to facilitate the long-lasting structural mod-
ifications that encode memory. One mechanism that has been
proposed for protein deposition is synaptic tagging (6), which
hypothesizes that synaptic activity creates a tag at the activated
synapse that directs the subsequent targeting of proteins syn-
thesized in the soma. Another proposed mechanism is dendritic
protein synthesis, which suggests that synaptic activity leads to
protein synthesis at activated synaptic sites (e.g., refs/ 3, 7, and
8). Although it remains to be tested directly, the latter scenario
is supported by observations that mRNA (9), polyribosomes, and
translation factors are present in the postsynaptic regions of
hippocampal neurons, and mRNAs can be translated in isolated
dendrites (10–12). Despite the importance of new protein syn-
thesis for LTP expression and memory retention, we know little
about how synaptic activity initiates protein translation in neu-
rons. Previous studies in other cell types have suggested that
translation activation and repression can be mediated by mod-
ulating the activity of various translation factors (13). Such
mechanisms may also be used by neurons, as suggested by results
of recent experiments. For instance, Wu et al. reported that
visual experience can stimulate polyadenylation as well as trans-
lation of CaMKII mRNA, although a causal relationship
between these events has not been established (14). The activity
of eukaryotic elongation factor 2 (eEF-2) is down-regulated by
visual stimulation-induced phosphorylation. This phosphoryla-
tion is mediated by an N-methyl-D-aspartate-receptor-
dependent activation of eEF-2 kinase (15, 16 ). A link between
synaptic activity and translation activation has also been
suggested recently by the observation that stimulation of
metabotropic glutamate receptors induces the translocation of
p90rsk kinase to polyribosomes (17). This translocation may be
responsible for the phosphorylation and activation of multiple
ribosome-binding proteins that are involved in translation
control (18).
Recent studies have characterized a rapamycin-sensitive trans-
lational signaling pathway that regulates the translation of a
specific subclass of mRNAs in mammalian cells (18). Various
growth factors can stimulate this pathway, leading to the phos-
phorylation and activation of mammalian target of rapamycin
(mTOR), a serinethreonine protein kinase that modulates the
activity of several translation regulatory factors. mTOR activa-
tion can be specifically inhibited by rapamycin (19). Activation
of mTOR can contribute to translational initiation by phosphor-
ylating proteins that bind eukaryotic initiation factor-4E (eIF-
4E); these proteins are known as eIF4E-binding proteins (4E-
BPs). The association of 4E-BPs with eIF-4E inhibits the ability
of eIF-4E to associate with eIF-4G and initiate translation. The
phosphorylation of 4E-BPs by mTOR or other kinases results in
their dissociation from eIF-4E and a subsequent initiation of
translation (20, 21). mTOR kinase may also regulate translation
by direct or indirect phosphorylation other translation-related
protein factors such as p70S6K and eIF-4GI (22). p70S6K is
present at synapses most likely by means of its association with
the PDZ-domain-containing protein neurabin (23).
We have conducted experiments to assess the possible in-
volvement of the rapamycin-sensitive pathway in translation-
dependent synaptic plasticity. We show here that several key
components of this signaling pathway are present in the hip-
pocampus and are enriched at postsynaptic sites. Disruption of
this signaling pathway with rapamycin inhibits the expression of
both enduring LTP and brain-derived neurotrophic factor
(BDNF)-induced synaptic potentiation in hippocampal slices.
Abbreviations: LTP, long-term potentiation; mTOR, mammalian target of rapamycin; eIF-
4E, eukaryotic initiation factor-4E; 4E-BP, eIF-4E-binding protein; BDNF, brain-derived
neurotrophic factor; ACSF, artificial cerebrospinal fluid; fEPSP, field excitatory postsynaptic
potential.
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These results demonstrate the presence of this translational
signaling pathway at synaptic sites and its essential role in
long-term plasticity in the hippocampus. We propose that this
pathway may provide a mechanism for the regulation of protein
synthesis at synapses.
Materials and Methods
Antibodies. Anti-eIF-4E mouse antibody was from Transduction
Laboratories (Lexington, KY); anti-4E-BP1 and 4E-BP2 rabbit
antibodies were made in-house (N.S.); anti-mTOR rabbit anti-
body was provided by R. T. Abraham (Mayo Clinic). All
antibodies were affinity-purified. Antibody dilutions used in
Western blot analysis: anti-eIF-4E, 1:250; anti-4E-BP1, 1:250;
anti-4E-BP2, 1:250; anti-mTOR, 1:250. Antibody dilutions used
in immunostaining: anti-eIF-4E, 1:100; anti-4E-BP1, 1:50; anti-
4E-BP2, 1:50; anti-mTOR, 1:200.
Western Blot Analysis. Adult hippocampi were homogenized in
cold PBS containing 0.5% Triton X-100 and proteinase inhibi-
tors at 4°C. The homogenate was boiled for 3 min, cooled on ice,
and centrifuged for 10 min at 4°C. The supernatant was trans-
ferred to fresh tubes, and the protein concentration was deter-
mined by the Bradford method (Bio-Rad). Ten micrograms of
total protein was mixed with 2 SDS gel-loading buffer (100 mM
TrisCl200 mM DTT4% SDS0.2% bromophenol blue20%
glycerol), heated for 2 min at 95°C, and run on SDS-4–15%
polyacrylamide gel. Protein transfer and Western blot analysis
were performed according to Harlow and Lane (24). Target
proteins were detected by using enhanced chemiluminescence
reagents (Amersham Pharmacia).
Immunostaining. Slices (500 m) were fixed on ice with 4%
paraformaldehyde and 0.2% glutaraldehyde for 1 h and trans-
ferred to PBS on ice for overnight. Sections (50 m) were then
cut by using a Vibratome and a sapphire knife. The sections were
incubated sequentially with 0.7% Triton X-100 in PBS at room
temperature for 1 h followed by two 5-min washes with PBS; 0.1
M glycine in PBS at room temperature for 1 h followed by one
5-min wash with ddH2O; 1% sodium borohydride in ddH2O at
room temperature for 20 min followed by one 5-min wash with
ddH2O; preblock buffer (0.05% Triton-X, 5% goat serum in
PBS) at 4°C for 1.5 h; primary antibodies in preblock buffer at
4°C overnight. After primary antibody incubation, the sections
Fig. 1. Western blot analysis of eIF-4E, 4E-BP1, 4E-BP2, and mTOR proteins
in hippocampal lysates. Total lysates of the rat adult hippocampus were used
for Western blot analysis, with antibodies specific for eIF-4E, 4E-BP1, 4E-BP2,
and mTOR (see Material and Methods for details). The size of protein markers
is labeled on the left of each blot. Note the doublet bands detected by
anti-eIF-4E, 4E-BP1, and 4E-BP2 (arrowheads).
Fig. 2. Spatial distribution of eIF-4E, 4E-BP1, 4E-BP2, and mTOR in hippocam-
pal slices. Shown are confocal images of hippocampal slices stained with
primary antibodies against purified rabbit IgG (control staining), eIF4-E, 4E-
BP1, 4E-BP2, or mTOR proteins, and FITC-conjugated secondary antibodies.
Note the staining signals for eIF-4E, 4E-BP1, 4E-BP2, and mTOR in cell bodies
and dendrites. Because mTOR is mainly a membrane protein, little signal for
this protein is detected in the cytoplasm of the cell body (asterisk). c, cell body;
d, dendrites; s, stratum radiatum; m, molecular layer.
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were washed for 30 min three times with preblock buffer and
then incubated with FITC-conjugated secondary antibodies
(Jackson ImmunoResearch; dilution, 1:200) at room tempera-
ture for 1 h followed by one 3-min wash with preblock buffer and
two 30-min washes with PBS. Sections were mounted in Immuno
Floure Mounting Medium (ICN). Cultured hippocampal cells
(P2, 14 DIV) were fixed in cold 4% paraformaldehyde in PBS
containing 4% sucrose on ice for 20 min and then in cold
(20°C) methanol on ice for 10 min. The fixed cells were
incubated with 0.2% Triton X-100 in PBS for 10 min and then
with preblock buffer at 4°C for 1 h. The cells were incubated with
primary antibodies in preblock buffer overnight at 4°C, washed
(for 15 min three times) with preblock buffer at room temper-
ature, incubated with FITC- or Cy3-conjugated secondary an-
tibodies for 1 h and washed for 15 min once with preblock buffer
and for 15 min twice with PBS before mounted. Immunostained
specimens were viewed with an Olympus (New Hyde Park, NY)
confocal microscope. Images were recorded through standard
emission filters at contrast settings for which the crossover
between the two channels was negligible.
Electrophysiology. Hippocampal slices were prepared by using a
Stoelting tissue chopper from young (6- to 8-week-old) adult
male Sprague–Dawley rats or young (5- to 7-week-old) adult
male BALBc57 l mice. Before electrophysiological recording,
slices were stored for at least 1.5 h on a Millipore membrane
placed over a tissue culture dish containing oxygenated artificial
cerebrospinal f luid (ACSF) solution. The slice was exposed to
95% O25% CO2 circulating in an enclosed chamber. For
electrophysiological recordings, slices were submerged in a
stream of ACSF (119 mM NaCl2.5 mM KCl1.3 mM MgSO4
2.5 mM CaCl21.0 mM NaH2PO426.2 mM NaHCO311.0 mM
glucose) maintained at room temperature (22–25°C) and gassed
with 95% O25% CO2. Field excitatory postsynaptic potentials
(EPSPs) measured in stratum radiatum were evoked by stimu-
lation of the Schaffer collateral-commissural afferents (one
stimulation every 30 sec). Extracellular recording electrodes
were filled with 3 M NaCl. In L-LTP experiments, tetanic
stimulation was delivered at the test intensity in 1-sec trains at
100 Hz, with four trains delivered 5 min apart; slices were
maintained at 28°C.
Results
Previous studies have identified a rapamycin-sensitive signaling
pathway that regulates protein translation in mammalian cells
(20). We decided to test its involvement in hippocampal synaptic
plasticity. We first examined whether the components of this
pathway are present in the rat hippocampus. Western blot
analyses identified mTOR and its downstream targets or effec-
tors, including eIF-4E, 4E-BP1, and 4E-BP2 in hippocampal
lysates (Fig. 1). eIF-4E, 4E-BP1, and 4E-BP2 were detected as
multiple bands on Western blots, suggesting the existence of
phosphorylated forms as indicated by studies of other cell types
(25, 26).
Fig. 3. Synaptic localization of eIF-4E, 4E-BP1, 4E-BP2, and mTOR. (A)
Dissociated hippocampal neurons (P2; 14 DIV) were double-stained with
components of the mTOR pathway (first column) including anti-eIF-4E (a),
4E-BP1 (d), 4E-BP2 (g), mTOR (j), or PSD-95 (m) antibodies and anti-synapsin I
antibodies (second column) (b, e, h, and k). Signals from eIF-4E, 4E-BP1, 4E-BP2,
mTOR, and PSD-95, and signals from the corresponding anti-synapsin staining
on the same cells were overlaid in c, f, i, l, and o, respectively. In the overlaid
images, green signals were generated by anti-eIF-4E, 4E-BP1, 4E-BP2, mTOR,
or PSD-95 staining, red signals were generated by anti-synapsin staining, and
yellow signals resulted from the overlapping of green and red signals. Insets
in c, f, i, l, and o are the higher magnification images for the dendritic regions
marked by boxes. (B) Double-labeling of eIF-4E (a), 4E-BP1 (d), mTOR (g) with
PSD-95 (b, e, h). Signals from eIF-4E, 4E-BP1, and mTOR and signals from the
corresponding PSD-95 staining on the same cells were overlaid in c, f, l, and i,
respectively. Insets in c, f, and i are the higher magnification images for the
dendritic regions marked by boxes (green signals resulted from eIF-4E, 4E-BP1,
or mTOR staining; red signals from PSD-95 staining; yellow signals from the
overlapping of green and red signals). Arrows indicate the synaptic regions
that are double-stained. (Bar  50 m.)
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To determine the distribution patterns of these factors within
the hippocampus, we performed fluorescent immunostaining
with specific primary antibodies against eIF-4E, 4E-BP1, 4E-
BP2, and mTOR and FITC-conjugated secondary antibodies. By
confocal microscopy analysis, f luorescent signals from eIF-4E,
4E-BP1, 4E-BP2, and mTOR were observed in the CA1 region
of hippocampal slices (Fig. 2). Immunostaining for all the
proteins was clearly observed in both the cell body (stratum
pyramidale) and synaptic (stratum radiatum) regions of the
hippocampal slice. Immunopositive neurites radiating from im-
munopositive cell bodies strongly suggest dendritic localization
of these proteins (Fig. 2). Staining for these proteins was also
lower in the molecular layer (stratum lacunosum moleculare)
than in the stratum radiatum (Fig. 2).
To characterize further the subcellular distribution of these
factors in hippocampal neurons, we performed immunostaining
on neurons (P2) cultured in vitro for 2 weeks. As shown in Fig.
3A, all the factors exhibited a somatodendritic pattern of local-
ization. In the dendrites, eIF-4E, 4E-BP1, and 4E-BP2 were
distributed in a punctate pattern. Some of the immunopositive
puncta corresponded to synaptic regions as revealed by synapsin
double labeling. At high magnification, the immunostaining
signals for eIF-4E, 4E-BP1, and 4E-BP2 were seen to oppose and
slightly overlap with the signals for synapsin-I (a presynaptic
protein) staining, suggesting their localization on the postsyn-
aptic side (see Fig. 3 Ac, Af, and Ai Insets). In particular, 4E-BP2
seemed to be significantly enriched in the postsynaptic region
with a lower signal evident in the dendritic shaft, when compared
with eIF-4E and 4E-BP1. The mTOR-positive regions were
observed in the dendritic shaft in a diffuse pattern that extended
into synaptic regions (Fig. 3Al). Consistent with the notion of
postsynaptic localization of these proteins, double labeling with
PSD-95 showed the signals from eIF-4E, 4E-BP1, and mTOR at
synaptic regions almost completely overlapped with PSD-95
signals (Fig. 3B).
To determine the functional significance of mTOR-mediated
signaling in LTP expression, we examined the sensitivity of both
early- and late-phase LTP to inhibition by rapamycin. LTP was
induced by four trains of 100-Hz stimulation (1 sec each)
separated by 5-min intervals. As shown in Fig. 4, the presence of
200 nM rapamycin inhibited the magnitude of late-phase LTP
(L-LTP, measured 230–240 min after the last tetanus), whereas
the early phase of LTP (E-LTP, measured 50–60 min after the
last tetanus) was unaffected [mean percent of baseline 50–60
min after tetanus, 164.9  6.6; 230–240 min after tetanus,
127.5  6.4 (n  8)]. In contrast, application of the same
concentration of FK506, a drug that has a similar structure and
can bind to the same receptor (FKBP12) as rapamycin but does
not inhibit mTOR activity (19), did not affect the magnitude of
either early- or late-phase LTP [mean percent of baseline 50–60
Fig. 4. Rapamycin decreases the magnitude of late-phase LTP in hippocampal slices. Shown are ensemble averages for all DMSO, FK506, and rapamycin
experiments (n  6, 9, and 8, respectively). All drugs were applied in the ACSF at least 30 min before the first tetanus. Mean DMSO control fEPSP slope values
were 0.20 0.01 mV/msec before LTP induction, and 0.35 0.03 mV/msec 220–240 min after LTP induction. Mean FK506-treated fEPSP slope values were 0.21
0.02 mV/msec before LTP induction, and 0.30  0.09 mV/msec 220–240 min after LTP induction. Mean rapamycin-treated fEPSP slope values were 0.24  0.05
mV/msec before LTP induction, and 0.31  0.07 mV/msec 220–240 min after LTP induction. The control pathways for FK506 and rapamycin experiments are
symbolized by the filled inverted triangle and the open circles, respectively.
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min after tetanus, 183.6  10.8; 220–240 min after tetanus,
158.6  11.4 (n  9)]. Furthermore, FK506-treated slices were
indistinguishable from vehicle (DMSO)-control-treated slices
[mean percent of baseline 50–60 min after tetanus, 184.0  7.0;
230–240 min after tetanus, 173.4  8.7 (n  6)]. Rapamycin-
treated slices exhibited significantly less L-LTP than either
FK-506- (P  0.05) or DMSO-treated (P  0.05) slices. We also
monitored the basal synaptic transmission from a second path-
way in the same slices on which experiments were performed,
and found rapamycin did not affect it during the process of
recording (Fig. 4). These results demonstrate a role for mTOR
in L-LTP expression.
Previous studies have suggested that BDNF plays a role in
L-LTP expression (27, 28). In addition, BDNF-induced synaptic
enhancement requires new protein synthesis (3). Thus, we
examined the effect of rapamycin on BDNF-induced synaptic
potentiation. Slices were pretreated with either rapamycin or a
vehicle control for 30 min before the addition of BDNF to the
medium. As shown in Fig. 5, BDNF applied in the presence of
control ACSF enhanced synaptic transmission as reported (3, 29)
[mean percent of baseline 50–60 min after the onset of BDNF
application: control, 186.2  17.0% (n  6)]. In the presence of
rapamycin, however, BDNF failed to enhance synaptic strength
[mean percent of baseline 50–60 min after the onset of BDNF
application: rapamycin, 113.2  5.5% (n  6)]. Taken together,
these results show that plasticity induced by two different means
relies on rapamycin-sensitive signaling.
Discussion
Pharmacological studies with protein translation inhibitors have
pointed to a requirement for new protein synthesis during
BDNF-induced potentiation (3) and the late phase of LTP (1,
28). We have examined the potential role of a rapamycin-
sensitive translational signaling pathway in hippocampal synaptic
plasticity. Our Western blot analyses and immunostaining stud-
ies demonstrated the presence of several key components of this
pathway, including mTOR, eIF-4E, 4E-BP1, and 4E-BP2 in the
rat hippocampus; immunopositive labeling for all proteins was
evident in both the cell body and dendritic layers of the hip-
pocampal slice. Double-immunolabeling studies in cultured hip-
pocampal neurons revealed that these proteins are also present
at postsynaptic sites. This pattern of localization suggests that
these proteins may mediate translational regulation at postsyn-
aptic sites and couple synaptic events with the protein translation
machinery. Consistent with this suggestion, our experiments
demonstrate a requirement for this signaling pathway in both
L-LTP- and BDNF-induced synaptic potentiation.
Pretreatment of hippocampal slices with rapamycin inhibited
both BDNF- and high-frequency stimulation-induced synaptic
plasticity, albeit with different temporal profiles. Rapamycin
inhibited the early aspect BDNF-induced potentiation. In con-
trast, the early phase of LTP was unaffected by rapamycin, but
the late phase (e.g., 2–3 h after tetanus) was significantly
reduced. These temporal profiles of inhibition parallel the
profiles observed with conventional protein synthesis inhibitors
(1, 3, 28).
These experiments do not allow us to ascertain the location of
the activity of the rapamycin-sensitive kinase during plasticity
expression. Our immunostaining studies show the presence of
mTOR in both the soma and the dendrites of hippocampal
neurons. Rapamycin was present in the ACSF beginning 30 min
before the initiation of potentiation and maintained at the same
concentration for the duration of the experiment. The very early
inhibition of the BDNF-induced potentiation is consistent with
a local block of mTOR activity in dendrites or synaptic sites. The
cell body layer is 500 m from the recording making it
implausible that rapamycin is inhibiting somatically synthesized
proteins destined for synaptic sites. Consistent with this notion,
the downstream substrates of mTOR, 4E-BP1, and 4E-BP2, are
enriched at the postsynaptic sites, suggesting a local function of
mTOR on the regulation of synaptic protein synthesis. In
addition, recent work performed in cultured Aplysia sensory-
motor neuron system have demonstrated a synaptic role of the
rapamycin-sensitive signaling in LTF (30). In this experiment,
the inhibition of late-, but not early-, phase LTP is consistent
with either a somatic or dendritic location for the rapamycin-
sensitive store. If rapamycin is acting at the soma, the long-
latency inhibition could reflect either the transport time for
synaptically generated signals to travel to the cell body and
stimulate translation, or the transport time for newly synthesized
proteins to be delivered to synaptic sites, or both. Alternatively,
the long-latency inhibition by rapamycin could reflect the time
required for mRNA transport to the dendrites. According to this
idea, LTP-induced transcription is followed by mRNA transport
to dendrites and then local, rapamycin-sensitive translation
occurs, the protein products of which allow the synaptic poten-
tiation to endure.
We currently do not know the mechanism by which synaptic
activity activates this signaling pathway during LTP expression.
Previous studies have identified protein kinase B (PKB, Akt) and
phosphotidylinositol-3-kinase (PI3K) as the upstream regulators
of mTOR (25, 31), and various growth factors have been shown
to activate PI3K and PKB (32). As neurotrophins may be
released during LTP (28, 33, 34), they may initiate mTOR
signaling through PI3K and PKB activation. The second mes-
senger cAMP produced after synaptic activation may also acti-
vate mTOR signaling by cAMP-dependent protein kinase A
(PKA), because PKA is able to activate PKB (35). Future studies
will establish a molecular connection between synaptic activity
and mTOR translational signaling activation.
Dendritic protein synthesis at synaptic sites has been proposed
as a mechanism that might contribute to local synaptic changes
during LTP expression (7, 36, 37). Consistent with this hypoth-
esis, various mRNAs and polyribosomes are present in these
areas (9, 38). Recent studies have also demonstrated the exis-
tence of endoplasmic reticulum and Golgi apparatus in the
postsynaptic site opposing synaptic boutons, suggesting the
presence of translational and posttranslational modification
Fig. 5. Rapamycin prevents BDNF-induced synaptic potentiation in hip-
pocampal slices. Shown are ensemble averages for all control and rapamycin
experiments. BDNF (50 ng/ml) was applied in the ACSF at the time indicated by
the bar. Mean control fEPSP slope values were 0.13  0.03 mV/msec before
BDNF application and 0.23  0.04 mV/msec after BDNF application. Mean
rapamycin-treated fEPSP slope values were 0.16 0.01 mV/msec before BDNF
application and 0.18  0.01 mV/msec after BDNF application.
Tang et al. PNAS  January 8, 2002  vol. 99  no. 1  471
N
EU
RO
BI
O
LO
G
Y
machinery in the postsynaptic regions (39, 40). We showed here
in cultured hippocampal neurons that eIF-4E, 4E-BP1, 4E-BP2,
and mTOR are also present in the postsynaptic region. These
findings put the mTOR translational signaling in a position to
regulate local protein synthesis during long-term synaptic plas-
ticity. This idea is supported by the recent observation that
BDNF induces a rapamycin-sensitive phosphorylation of eIF4E
and 4EBP1 (41).
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